Targets — browse / sort / filter (view)
Data license: CC BY 4.0 · Data source: apt-scout automated curation pipeline (E. Dohi, NCNP) — values harvested from public databases; raw source stored per target
- id
- UniProt accession (human). Links to uniprot.org.
- gene_symbol
- Gene symbol (e.g. ITGB3).
- protein_name
- Protein name (UniProt).
- tier
- Tier 1 = PDB-anchored; Tier 1.5 = AlphaFold-confident.
- has_structure
- 1 if the target protein has a reported experimental 3D structure (PDB). This is the CORE requirement the aptamer-Kd layer is built around — filter to 1 for the structure-backed set.
- evidence_priority
- DETERMINISTIC, reproducible prioritisation (0-1) computed at build time from real harvested columns: 0.35*experimental-structure(PDB=1 / AlphaFold-only=0.3) + 0.30*Open-Targets-top-disease-score + 0.20*PREDICTED-surface-accessibility(A_surface=1) + 0.15*EV-detection(EV-Map). A transparent ranking AID, not a validation; the surface/EV terms are PREDICTIONS/DETECTIONS, not measured EV-surface exposure. Recomputable exactly from this DB.
- has_activation_state_pdb_pair
- 1 if a curated ACTIVE/INACTIVE PDB pair exists (only 11 targets).
- in_cev_map
- Detected in the EV-Map plasma-EV dataset (Rai & Greening 2025, Nat Cell Biol, 10.1038/s41556-025-01795-7) = 3,422 apt-scout targets (broad detected proteome). The EV-Map CONSERVED EV proteome is 182 proteins (42 non-EV); apt-scout matches 104 of these conserved EV-hallmark proteins as targets by gene (the other 78 are not apt-scout targets). Use the ev_hallmark_targets query for that subset. IMPORTANT: EV-Map detection means the protein is EV CARGO (present in the vesicle) — it does NOT mean surface-exposed. Rai & Greening 2025 run a separate membrane-impermeant biotinylation assay giving a 151-protein SURFACEOME, and show the conserved SDCBP/syntenin is luminal (not surface-accessible). For genuine EV-surface accessibility use that 151-protein set, not EV-Map presence.
- has_known_aptamer
- 1 if PubMed '(gene) AND (aptamer OR SELEX)' returned any hit (KEYWORD co-mention, includes false positives — NOT a verified aptamer). For verified aptamers with Kd, see the Binding-affinities (v_kd) layer.
- opentargets_top_disease_score
- Open Targets association score (0-1).
- aptamer_count_pubmed
- Number of PubMed hits for (this protein) AND (aptamer OR SELEX). Keyword co-occurrence — verify each (many co-mention without a real aptamer).
- aptamer_pmids
- The actual PubMed IDs behind the aptamer evidence — click each to read the paper. This is the source of the 'has aptamer' claim.
- surface_class
- PREDICTED membrane topology (HPA-derived, not a measurement): A_surface = integral/ecto cell-surface (predicted EV-surface accessible); A2_pm_peripheral = plasma-membrane cytoplasmic-leaflet (SRC/LYN/RHOA, predicted not reachable); A_assoc = secreted/corona; B_cargo = luminal cargo; unknown = no HPA localization. Lipid asymmetry can partially flip (PS via scramblase); confirm by protease-protection / intact-EV surface labelling. See v_surface_targets.
78 rows where has_known_aptamer = 1, surface_class = "A2_pm_peripheral" and tier = "Tier 1" sorted by evidence_priority descending
This data as json, CSV (advanced)
Suggested facets: aptamer_count_pubmed
| id | gene_symbol | protein_name | tier | evidence_priority ▲ | has_structure | surface_class | pdb_count_total | alphafold_mean_pLDDT | has_cryoEM | has_activation_state_pdb_pair | activation_state_pdb_active | activation_state_pdb_inactive | has_known_aptamer | aptamer_count_pubmed | aptamer_pmids | in_cev_map | opentargets_top_disease_name | opentargets_top_disease_score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P15056 | BRAF | Serine/threonine-protein kinase B-raf | Tier 1 | 0.803 | 1 | A2_pm_peripheral | 100 | 66.38 | 0 | 0 | 1 | 6 | 39624124, 34874026, 33497198, 31726389, 24486214, 11856330 | 1 | cardiofaciocutaneous syndrome | 0.8764542776642054 | ||
| P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | Tier 1 | 0.799 | 1 | A2_pm_peripheral | 75 | 67.5 | 0 | 0 | 1 | 4 | 15112994, 12173045, 11856330, 9883908 | 1 | Noonan syndrome | 0.8625147809861142 | ||
| Q06187 | BTK | Tyrosine-protein kinase BTK | Tier 1 | 0.794 | 1 | A2_pm_peripheral | 100 | 84.44 | 0 | 0 | 1 | 1 | 41951939 | 1 | X-linked agammaglobulinemia | 0.8454716106068291 | ||
| Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Tier 1 | 0.788 | 1 | A2_pm_peripheral | 94 | 83.25 | 0 | 0 | 1 | 1 | 29580944 | 1 | cardiofaciocutaneous syndrome | 0.825549979325162 | ||
| P01111 | NRAS | GTPase NRas | Tier 1 | 0.783 | 1 | A2_pm_peripheral | 35 | 92.06 | 0 | 0 | 1 | 2 | 39952900, 39371477 | 1 | Noonan syndrome 6 | 0.8087775198380727 | ||
| O60674 | JAK2 | Tyrosine-protein kinase JAK2 | Tier 1 | 0.78 | 1 | A2_pm_peripheral | 100 | 86.88 | 0 | 0 | 1 | 8 | 41455398, 34121564, 32985358, 31279934, 30415442, 25809097, 22411871, 20711698 | 1 | polycythemia vera | 0.8000866241942614 | ||
| P01137 | TGFB1 | Transforming growth factor beta-1 proprotein | Tier 1 | 0.78 | 1 | A2_pm_peripheral | 20 | 79.56 | 1 | 0 | 1 | 4 | 38132522, 32370304, 16775010, 11856769 | 1 | Camurati-Engelmann disease | 0.7995305374459716 | ||
| P98170 | XIAP | E3 ubiquitin-protein ligase XIAP | Tier 1 | 0.78 | 1 | A2_pm_peripheral | 74 | 74.25 | 0 | 0 | 1 | 4 | 35383192, 29864441, 27514505, 26318819 | 1 | X-linked lymphoproliferative disease | 0.8013347966323413 | ||
| Q9UHD9 | UBQLN2 | Ubiquilin-2 | Tier 1 | 0.778 | 1 | A2_pm_peripheral | 4 | 61.03 | 0 | 0 | 1 | 2 | 23541532 | 1 | amyotrophic lateral sclerosis type 15 | 0.7942015735994536 | ||
| O15294 | OGT | UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit | Tier 1 | 0.77 | 1 | A2_pm_peripheral | 44 | 93.06 | 0 | 0 | 1 | 2 | 36868188, 36626902 | 1 | intellectual disability, X-linked 106 | 0.7660009745204424 | ||
| Q92743 | HTRA1 | Serine protease HTRA1 | Tier 1 | 0.768 | 1 | A2_pm_peripheral | 18 | 83.25 | 1 | 0 | 1 | 1 | 31988066 | 1 | cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 | 0.7611877816680132 | ||
| P35221 | CTNNA1 | Catenin alpha-1 | Tier 1 | 0.765 | 1 | A2_pm_peripheral | 10 | 82.94 | 1 | 0 | 1 | 2 | 40265971 | 1 | Butterfly-shaped pigment dystrophy | 0.7487735496199569 | ||
| P26038 | MSN | Moesin | Tier 1 | 0.755 | 1 | A2_pm_peripheral | 10 | 86.38 | 0 | 0 | 1 | 65 | 41813080, 41784619, 41611946, 40904334, 40886652, 40258621, 40222299, 39454415, 39053429, 38856817, 38759442, 38687941, 38561432, 38446130, 38349197, 38295649, 38266273, 37869770, 37806507, 37423650, 37353120, 37062561, 37058944, 36982925, 36843953, 36700559, 36562728, 36179642, 35026109, 34893239, 34538325, 33960345, 33727809, 33528465, 33149582, 32882423, 32291531, 32170403, 31872318, 31792209, 31213813, 31072481, 30985076, 30865739, 32254866, 29955964, 29568450, 29136862, 28917759, 28832225 | 1 | combined immunodeficiency due to moesin deficiency | 0.7157135146765757 | ||
| P84077 | ARF1 | ADP-ribosylation factor 1 | Tier 1 | 0.755 | 1 | A2_pm_peripheral | 36 | 85.94 | 1 | 0 | 1 | 3 | 30965174, 11320245 | 1 | periventricular nodular heterotopia 8 | 0.7173626622431929 | ||
| Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | Tier 1 | 0.753 | 1 | A2_pm_peripheral | 41 | 73.69 | 0 | 0 | 1 | 2 | 32636813, 20564698 | 1 | intellectual developmental disorder with macrocephaly, seizures, and speech delay | 0.7110292416229067 | ||
| Q13546 | RIPK1 | Receptor-interacting serine/threonine-protein kinase 1 | Tier 1 | 0.749 | 1 | A2_pm_peripheral | 39 | 69.75 | 1 | 0 | 1 | 2 | 41290466, 35919280 | 1 | immunodeficiency 57 | 0.698121745966467 | ||
| P50148 | GNAQ | Guanine nucleotide-binding protein G(q) subunit alpha | Tier 1 | 0.748 | 1 | A2_pm_peripheral | 30 | 93.0 | 1 | 0 | 1 | 1 | 40015005 | 1 | Sturge-Weber syndrome | 0.6941111530708174 | ||
| P61586 | RHOA | Transforming protein RhoA | Tier 1 | 0.744 | 1 | A2_pm_peripheral | 100 | 93.56 | 0 | 0 | 1 | 4 | 25645980, 19389625, 12927206, 12123800 | 1 | ectodermal dysplasia with facial dysmorphism and acral, ocular, and brain anomalies | 0.6804889074382072 | ||
| Q00535 | CDK5 | Cyclin-dependent kinase 5 | Tier 1 | 0.744 | 1 | A2_pm_peripheral | 10 | 91.56 | 0 | 0 | 1 | 4 | 33291667, 33200349 | 1 | Alzheimer disease | 0.6800338890220147 | ||
| O95786 | RIGI | Antiviral innate immune response receptor RIG-I | Tier 1 | 0.735 | 1 | A2_pm_peripheral | 44 | 85.19 | 1 | 0 | 1 | 6 | 34487794, 33253193, 32946572, 31600868, 26018150, 22127865 | 1 | Singleton-Merten dysplasia | 0.6485708110478319 | ||
| P26196 | DDX6 | Probable ATP-dependent RNA helicase DDX6 | Tier 1 | 0.734 | 1 | A2_pm_peripheral | 9 | 84.06 | 0 | 0 | 1 | 2 | 34132569 | 1 | intellectual developmental disorder with impaired language and dysmorphic facies | 0.6482686715821397 | ||
| P12931 | SRC | Proto-oncogene tyrosine-protein kinase Src | Tier 1 | 0.73 | 1 | A2_pm_peripheral | 78 | 83.44 | 0 | 1 | 1Y57 | 2SRC | 1 | 19 | 40569566, 39664567, 38471488, 35928129, 35859339, 34757788, 34083659, 33530373, 32668060, 30970280, 28701145, 26458993, 25645980, 23842900, 22693611, 22323540, 18985031, 18682833, 12842895 | 1 | cancer | 0.6343904000453656 |
| P61769 | B2M | Beta-2-microglobulin | Tier 1 | 0.725 | 1 | A2_pm_peripheral | 100 | 94.06 | 0 | 0 | 1 | 15 | 41850110, 40373155, 38904251, 40658810, 35026285, 32631049, 29281176, 28960840, 25100729, 20616783, 19137104, 17878167 | 1 | Immunodeficiency by defective expression of HLA class 1 | 0.6180318849819645 | ||
| P23921 | RRM1 | Ribonucleoside-diphosphate reductase large subunit | Tier 1 | 0.724 | 1 | A2_pm_peripheral | 12 | 92.25 | 1 | 0 | 1 | 1 | 21955496 | 1 | non-small cell lung carcinoma | 0.6122881671315019 | ||
| P43405 | SYK | Tyrosine-protein kinase SYK | Tier 1 | 0.723 | 1 | A2_pm_peripheral | 93 | 84.0 | 0 | 0 | 1 | 2 | 35782912, 31825964 | 1 | immunodeficiency 82 with systemic inflammation | 0.608506293550361 | ||
| P06241 | FYN | Tyrosine-protein kinase Fyn | Tier 1 | 0.721 | 1 | A2_pm_peripheral | 53 | 80.81 | 0 | 0 | 1 | 5 | 38559166, 37149826, 34757788, 32668060, 29754498 | 1 | chronic myelogenous leukemia | 0.6018224074412558 | ||
| P07947 | YES1 | Tyrosine-protein kinase Yes | Tier 1 | 0.716 | 1 | A2_pm_peripheral | 1 | 81.88 | 0 | 0 | 1 | 1 | 34757788 | 1 | chronic myelogenous leukemia | 0.5851678597856559 | ||
| P45984 | MAPK9 | Mitogen-activated protein kinase 9 | Tier 1 | 0.707 | 1 | A2_pm_peripheral | 5 | 81.44 | 0 | 0 | 1 | 1 | 41505229 | 1 | cancer | 0.5569349147269519 | ||
| P04406 | GAPDH | Glyceraldehyde-3-phosphate dehydrogenase | Tier 1 | 0.706 | 1 | A2_pm_peripheral | 21 | 98.12 | 1 | 0 | 1 | 11 | 39832592, 39429683, 35821507, 28131717, 26310631, 23215008, 37500700, 16115199 | 1 | neurodegenerative disease | 0.55307368855439 | ||
| O75534 | CSDE1 | Cold shock domain-containing protein E1 | Tier 1 | 0.704 | 1 | A2_pm_peripheral | 5 | 79.56 | 0 | 0 | 1 | 1 | 10101203 | 1 | neurodegenerative disease | 0.5472997885061864 | ||
| P67809 | YBX1 | Y-box-binding protein 1 | Tier 1 | 0.703 | 1 | A2_pm_peripheral | 11 | 61.84 | 0 | 0 | 1 | 9 | 31989173, 31160337, 22730292, 21245151, 16093451 | 1 | dengue disease | 0.5435698373845997 | ||
| P34947 | GRK5 | G protein-coupled receptor kinase 5 | Tier 1 | 0.702 | 1 | A2_pm_peripheral | 23 | 90.38 | 0 | 0 | 1 | 1 | 18230760 | 1 | venous thromboembolism | 0.5394311062516939 | ||
| Q92888 | ARHGEF1 | Rho guanine nucleotide exchange factor 1 | Tier 1 | 0.695 | 1 | A2_pm_peripheral | 7 | 73.19 | 0 | 0 | 1 | 6 | 25645980, 23757206, 25033804, 22689339, 19389625, 12123800 | 1 | immunodeficiency 62 | 0.5170912094162261 | ||
| P49327 | FASN | Fatty acid synthase | Tier 1 | 0.68 | 1 | A2_pm_peripheral | 34 | 85.44 | 1 | 0 | 1 | 1 | 41854184 | 1 | dengue disease | 0.46815584653391107 | ||
| Q07812 | BAX | Apoptosis regulator BAX | Tier 1 | 0.679 | 1 | A2_pm_peripheral | 37 | 85.94 | 0 | 0 | 1 | 21 | 41323565, 41237573, 40761795, 40148451, 39946362, 39318128, 37301952, 36907299, 36843953, 36309655, 32987067, 32486412, 31747745, 30005287, 27843907, 26325285, 24481451, 23582862, 23528042, 21563784, 21362508 | 1 | T-cell acute lymphoblastic leukemia | 0.4626258720529755 | ||
| P09104 | ENO2 | Gamma-enolase | Tier 1 | 0.676 | 1 | A2_pm_peripheral | 16 | 97.06 | 0 | 0 | 1 | 1 | 36384120 | 1 | neurodegenerative disease | 0.4533558777394424 | ||
| P07355 | ANXA2 | Annexin A2 | Tier 1 | 0.673 | 1 | A2_pm_peripheral | 41 | 94.25 | 0 | 0 | 1 | 12 | 40685636, 31029658, 29906496, 24489826, 35211356, 29982617, 27890659, 27777972, 26061649 | 1 | neurodegenerative disease | 0.4424399692174707 | ||
| Q15828 | CST6 | Cystatin-M | Tier 1 | 0.673 | 1 | A2_pm_peripheral | 5 | 90.44 | 0 | 0 | 1 | 1 | 27679852 | 1 | autosomal recessive hypohidrotic ectodermal dysplasia | 0.44403998062712996 | ||
| P52209 | PGD | 6-phosphogluconate dehydrogenase, decarboxylating | Tier 1 | 0.666 | 1 | A2_pm_peripheral | 4 | 96.81 | 0 | 0 | 1 | 1 | 31557732 | 1 | neurodegenerative disease | 0.4205455366275092 | ||
| Q8NB16 | MLKL | Mixed lineage kinase domain-like protein | Tier 1 | 0.665 | 1 | A2_pm_peripheral | 22 | 83.12 | 0 | 0 | 1 | 5 | 42019750, 38744189, 35919280 | 1 | chronic recurrent multifocal osteomyelitis | 0.41771763075738416 | ||
| P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | Tier 1 | 0.661 | 1 | A2_pm_peripheral | 32 | 84.31 | 1 | 0 | 1 | 1 | 35921069 | 1 | multiple myeloma | 0.40496963397728575 | ||
| P02686 | MBP | Myelin basic protein | Tier 1 | 0.658 | 1 | A2_pm_peripheral | 6 | 54.12 | 0 | 0 | 1 | 21 | 42058742, 39442496, 38852383, 38217663, 38070612, 37500079, 33676686, 33195056, 32365011, 29484603, 26686919, 25202925, 23998713, 22736004, 10848986, 30982509, 24512542, 19457263 | 1 | alcohol drinking | 0.391844482483692 | ||
| P24941 | CDK2 | Cyclin-dependent kinase 2 | Tier 1 | 0.652 | 1 | A2_pm_peripheral | 100 | 88.44 | 0 | 1 | 1QMZ | 1HCK | 1 | 24 | 33981223, 26972431, 21616931, 21059336, 20394401, 19320493, 18495468, 18186614, 11071782, 11106396, 9826690, 9826689, 8606778, 11566434 | 1 | neurodegenerative disease | 0.37316884263655814 |
| P06702 | S100A9 | Protein S100-A9 | Tier 1 | 0.651 | 1 | A2_pm_peripheral | 13 | 94.31 | 1 | 0 | 1 | 9 | 41924874, 41505229, 41477217, 40215752, 39317671, 37879125, 35724603, 33534888, 32478041 | 1 | inborn error of immunity | 0.36994943453938645 | ||
| Q99418 | CYTH2 | Cytohesin-2 | Tier 1 | 0.651 | 1 | A2_pm_peripheral | 11 | 84.62 | 0 | 0 | 1 | 2 | 23757206, 15277685 | 1 | neurodegenerative disease | 0.3695798546847018 | ||
| P43652 | AFM | Afamin | Tier 1 | 0.649 | 1 | A2_pm_peripheral | 3 | 90.5 | 0 | 0 | 1 | 181 | 41981590, 41644987, 41639270, 41592438, 41405386, 41252929, 41187335, 41065720, 41003495, 40817942, 40487293, 40430051, 40279903, 40200829, 39916299, 39863729, 39852074, 39772502, 39421963, 39349658, 39299186, 39282756, 39167342, 39131199, 39032299, 38925633, 38646165, 38224944, 38136647, 38094082, 38074684, 37975892, 37678120, 37630325, 37611441, 37444259, 37442003, 37329944, 37232893, 37166710, 37144950, 37127843, 36861067, 36819738, 36759615, 36694259, 36587435, 36551097, 36340178, 36227568, 37400771, 27530235 | 1 | Abnormality of the skeletal system | 0.3630438694285995 | ||
| Q86UW9 | DTX2 | Probable E3 ubiquitin-protein ligase DTX2 | Tier 1 | 0.645 | 1 | A2_pm_peripheral | 4 | 71.81 | 0 | 0 | 1 | 3 | 36623457, 35569274, 24164310 | 1 | neurodegenerative disease | 0.34889093978477204 | ||
| P25054 | APC | Adenomatous polyposis coli protein | Tier 1 | 0.644 | 1 | A2_pm_peripheral | 31 | 0 | 0 | 1 | 39 | 41471356, 40788329, 40207978, 39796151, 39335496, 39189513, 38710049, 38509823, 37199793, 37185533, 36894782, 36882463, 36827736, 36252203, 35544380, 35490167, 34837173, 34708097, 34240523, 34008621, 32486960, 32429721, 32386347, 31937772, 31295701, 31249960, 30609568, 29886066, 29666278, 27736370, 27427891, 26552824, 26552816, 25059182, 24681393, 22236082, 19389630, 19029139, 9546673 | 0 | familial adenomatous polyposis 1 | 0.8462165290909345 | |||
| P07996 | THBS1 | Thrombospondin-1 | Tier 1 | 0.641 | 1 | A2_pm_peripheral | 11 | 84.25 | 0 | 0 | 1 | 6 | 35990694, 34248840, 31640794, 30884317, 24434496, 22314602 | 1 | autism spectrum disorder | 0.3356118729017016 | ||
| P28676 | GCA | Grancalcin | Tier 1 | 0.641 | 1 | A2_pm_peripheral | 4 | 81.31 | 0 | 0 | 1 | 7 | 40480702, 39153834, 35029036, 24818254, 22915350, 17673982, 11058113 | 1 | intelligence | 0.33779315817113664 |
Advanced export
JSON shape: default, array, newline-delimited
CREATE VIEW v_targets AS
SELECT f.id, n.gene_symbol, n.protein_name, tg.tier,
-- evidence_priority: DETERMINISTIC, reproducible from real DB columns (no LLM).
-- Transparent weights over harvested evidence: structure 0.35, disease importance
-- 0.30 (Open Targets top-disease score), PREDICTED surface accessibility 0.20,
-- EV detection 0.15. A heuristic ranking aid, not a validation; surface/EV terms
-- are predictions/detections, NOT measured EV-surface exposure.
ROUND(
0.35*(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1.0
WHEN CAST(COALESCE(NULLIF(f.alphafold_mean_pLDDT,''),'0') AS REAL)>0 THEN 0.3 ELSE 0.0 END)
+ 0.30*MIN(CAST(COALESCE(NULLIF(f.opentargets_top_disease_score,''),'0') AS REAL), 1.0)
+ 0.20*(CASE sc.surface_class WHEN 'A_surface' THEN 1.0 WHEN 'A_assoc' THEN 0.5 WHEN 'A2_pm_peripheral' THEN 0.2 ELSE 0.0 END)
+ 0.15*(CASE WHEN CAST(COALESCE(f.in_cev_map,0) AS INTEGER)=1 THEN 1.0 ELSE 0.0 END)
, 3) AS evidence_priority,
(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1 ELSE 0 END) AS has_structure,
sc.surface_class,
f.pdb_count_total, f.alphafold_mean_pLDDT, f.has_cryoEM,
f.has_activation_state_pdb_pair, f.activation_state_pdb_active, f.activation_state_pdb_inactive,
f.has_known_aptamer, f.aptamer_count_pubmed, ap.aptamer_pmids,
f.in_cev_map, f.opentargets_top_disease_name, f.opentargets_top_disease_score
FROM v_target_full f
LEFT JOIN target_names n ON n.target_id=f.id
LEFT JOIN targets tg ON tg.id=f.id
LEFT JOIN target_aptamer_pmids ap ON ap.target_id=f.id
LEFT JOIN membrane_surface_class sc ON sc.target_id=f.id;